http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 11 Mar 2026 16:32:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Relay+Therapeutics%2C+Inc.++For%3A+Mar+09++Filed+by%3A+Catinazzo+Thomas/26146585.html si-local-file:///var/storage/secattach/20260311/26146585.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Relay+Therapeutics%2C+Inc.++For%3A+Mar+09++Filed+by%3A+Catinazzo+Thomas/26146585.html Wed, 11 Mar 2026 16:32:00 -0400 O.40271399 RLAY http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Relay+Therapeutics%2C+Inc.++For%3A+Mar+09++Filed+by%3A+Catinazzo+Thomas/26146585.html si-local-file:///var/storage/secattach/20260311/26146585.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Relay+Therapeutics%2C+Inc.++For%3A+Mar+09++Filed+by%3A+Catinazzo+Thomas/26146585.html Wed, 11 Mar 2026 16:32:00 -0400 O.40271399 RLAY http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Relay+Therapeutics%2C+Inc.++For%3A+Mar+06/26146298.html si-local-file:///var/storage/secattach/20260311/26146298.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Relay+Therapeutics%2C+Inc.++For%3A+Mar+06/26146298.html Wed, 11 Mar 2026 16:15:00 -0400 O.40271399 RLAY http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Relay+Therapeutics%2C+Inc.++For%3A+Mar+06/26146298.html si-local-file:///var/storage/secattach/20260311/26146298.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Relay+Therapeutics%2C+Inc.++For%3A+Mar+06/26146298.html Wed, 11 Mar 2026 16:15:00 -0400 O.40271399 RLAY http://www.streetinsider.com/SEC+Filings/Form++144++++++++Relay+Therapeutics%2C+Inc.+++++++++++++++Filed+by%3A+Catinazzo+Thomas/26132755.html si-local-file:///var/storage/secattach/20260309/26132755.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Relay+Therapeutics%2C+Inc.+++++++++++++++Filed+by%3A+Catinazzo+Thomas/26132755.html Mon, 09 Mar 2026 16:36:00 -0400 O.40271399 RLAY http://www.streetinsider.com/SEC+Filings/Form++144++++++++Relay+Therapeutics%2C+Inc.+++++++++++++++Filed+by%3A+Catinazzo+Thomas/26132755.html si-local-file:///var/storage/secattach/20260309/26132755.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Relay+Therapeutics%2C+Inc.+++++++++++++++Filed+by%3A+Catinazzo+Thomas/26132755.html Mon, 09 Mar 2026 16:36:00 -0400 O.40271399 RLAY http://www.streetinsider.com/Analyst+Comments/Relay+Therapeutics+%28RLAY%29+Reiterated+at+Market+Outperform+by+Citizens+Before+ESMO+Congress/26095390.html <p>Citizens analyst Silvan Turkcan reiterated a Market Outperform rating and $15.00 price target on Relay Therapeutics (NASDAQ: RLAY).</p><p>The analyst commented, "Relay Therapeutics is set to present, for the first time, Ph2 data for the 400mg BID fed zovegalisib cohort at ESMO Targeted Anticancer Therapies Congress 2026 on Monday, March 16. The ongoing ReDiscover-2 Phase 3 trial is evaluating 400 mg BID administered with food. Relay will look to demonstrate efficacy comparable to prior data (@600mg) to support the RP3D selection and further validate the ongoing registrational program. We maintain our Market Outperform rating and $15 DCF-derived price target."</p><p>For an analyst http://www.streetinsider.com/Analyst+Comments/Relay+Therapeutics+%28RLAY%29+Reiterated+at+Market+Outperform+by+Citizens+Before+ESMO+Congress/26095390.html Tue, 03 Mar 2026 05:08:24 -0400 RLAY http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 2, 2026</chron></span> /PRNewswire/ -- <b><i>The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology approaches is expanding treatment options. Additionally, the launch of emerging drugs such as Tinengotinib (TransThera Sciences), Rilvegostomig (AstraZeneca), Nanvuranlat (JPH203) (J-Pharma/<span value="ACORN:3216571029" idsrc="xmltag.org" >OHARA Pharmaceutical</span>), Tovecimig (CTX-009) (<span value="NASDAQ-NMS:CMPX" idsrc="xmltag.org" >Compass Therapeutics</span>), Lenvatinib mesylate (LENVIMA) (<span value="NYSE:MRK" idsrc="xmltag.org" >Merck</span>/Eisai), and others will further boost the market growth.</i></b></p> <div id="prni_dvprnejpg7689left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg7689left" title="DelveInsight Logo" src="https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg" alt="DelveInsight Logo" align="middle" /></div><p>Recently published Biliary Tract http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html Mon, 02 Mar 2026 17:31:00 -0400 2RH A.20986375 A.21423504 A.32165710 A.33353809 A.34272207 A.39985803 A.40151759 A.50100157 A.50113798 A.50113881 A.50114197 A.50202178 A.50202556 A.60012004 BOLD CMPX INCY JAZZ LLY LOXO MRK O.00000313 O.00002198 O.00037438 O.00050368 O.00052901 O.00160346 O.00160456 O.00637617 O.00644488 O.00823584 O.01304637 O.03044482 O.07639287 O.08528768 O.12498162 O.13804664 O.15817313 O.18722415 O.38725784 O.39100698 O.40271399 O.49925668 O.51354437 O.54940956 O.55342982 PFE RDHL REPL RLAY ROG S1GE34 SGEN http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 2, 2026</chron></span> /PRNewswire/ -- <b><i>The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology approaches is expanding treatment options. Additionally, the launch of emerging drugs such as Tinengotinib (TransThera Sciences), Rilvegostomig (AstraZeneca), Nanvuranlat (JPH203) (J-Pharma/<span value="ACORN:3216571029" idsrc="xmltag.org" >OHARA Pharmaceutical</span>), Tovecimig (CTX-009) (<span value="NASDAQ-NMS:CMPX" idsrc="xmltag.org" >Compass Therapeutics</span>), Lenvatinib mesylate (LENVIMA) (<span value="NYSE:MRK" idsrc="xmltag.org" >Merck</span>/Eisai), and others will further boost the market growth.</i></b></p> <div id="prni_dvprnejpg7689left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg7689left" title="DelveInsight Logo" src="https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg" alt="DelveInsight Logo" align="middle" /></div><p>Recently published Biliary Tract http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html Mon, 02 Mar 2026 17:31:00 -0400 2RH A.20986375 A.21423504 A.32165710 A.33353809 A.34272207 A.39985803 A.40151759 A.50100157 A.50113798 A.50113881 A.50114197 A.50202178 A.50202556 A.60012004 BOLD CMPX INCY JAZZ LLY LOXO MRK O.00000313 O.00002198 O.00037438 O.00050368 O.00052901 O.00160346 O.00160456 O.00637617 O.00644488 O.00823584 O.01304637 O.03044482 O.07639287 O.08528768 O.12498162 O.13804664 O.15817313 O.18722415 O.38725784 O.39100698 O.40271399 O.49925668 O.51354437 O.54940956 O.55342982 PFE RDHL REPL RLAY ROG S1GE34 SGEN http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 2, 2026</chron></span> /PRNewswire/ -- <b><i>The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology approaches is expanding treatment options. Additionally, the launch of emerging drugs such as Tinengotinib (TransThera Sciences), Rilvegostomig (AstraZeneca), Nanvuranlat (JPH203) (J-Pharma/<span value="ACORN:3216571029" idsrc="xmltag.org" >OHARA Pharmaceutical</span>), Tovecimig (CTX-009) (<span value="NASDAQ-NMS:CMPX" idsrc="xmltag.org" >Compass Therapeutics</span>), Lenvatinib mesylate (LENVIMA) (<span value="NYSE:MRK" idsrc="xmltag.org" >Merck</span>/Eisai), and others will further boost the market growth.</i></b></p> <div id="prni_dvprnejpg7689left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg7689left" title="DelveInsight Logo" src="https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg" alt="DelveInsight Logo" align="middle" /></div><p>Recently published Biliary Tract http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html Mon, 02 Mar 2026 17:31:00 -0400 2RH A.20986375 A.21423504 A.32165710 A.33353809 A.34272207 A.39985803 A.40151759 A.50100157 A.50113798 A.50113881 A.50114197 A.50202178 A.50202556 A.60012004 BOLD CMPX INCY JAZZ LLY LOXO MRK O.00000313 O.00002198 O.00037438 O.00050368 O.00052901 O.00160346 O.00160456 O.00637617 O.00644488 O.00823584 O.01304637 O.03044482 O.07639287 O.08528768 O.12498162 O.13804664 O.15817313 O.18722415 O.38725784 O.39100698 O.40271399 O.49925668 O.51354437 O.54940956 O.55342982 PFE RDHL REPL RLAY ROG S1GE34 SGEN http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 2, 2026</chron></span> /PRNewswire/ -- <b><i>The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology approaches is expanding treatment options. Additionally, the launch of emerging drugs such as Tinengotinib (TransThera Sciences), Rilvegostomig (AstraZeneca), Nanvuranlat (JPH203) (J-Pharma/<span value="ACORN:3216571029" idsrc="xmltag.org" >OHARA Pharmaceutical</span>), Tovecimig (CTX-009) (<span value="NASDAQ-NMS:CMPX" idsrc="xmltag.org" >Compass Therapeutics</span>), Lenvatinib mesylate (LENVIMA) (<span value="NYSE:MRK" idsrc="xmltag.org" >Merck</span>/Eisai), and others will further boost the market growth.</i></b></p> <div id="prni_dvprnejpg7689left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg7689left" title="DelveInsight Logo" src="https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg" alt="DelveInsight Logo" align="middle" /></div><p>Recently published Biliary Tract http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html Mon, 02 Mar 2026 17:31:00 -0400 2RH A.20986375 A.21423504 A.32165710 A.33353809 A.34272207 A.39985803 A.40151759 A.50100157 A.50113798 A.50113881 A.50114197 A.50202178 A.50202556 A.60012004 BOLD CMPX INCY JAZZ LLY LOXO MRK O.00000313 O.00002198 O.00037438 O.00050368 O.00052901 O.00160346 O.00160456 O.00637617 O.00644488 O.00823584 O.01304637 O.03044482 O.07639287 O.08528768 O.12498162 O.13804664 O.15817313 O.18722415 O.38725784 O.39100698 O.40271399 O.49925668 O.51354437 O.54940956 O.55342982 PFE RDHL REPL RLAY ROG S1GE34 SGEN http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 2, 2026</chron></span> /PRNewswire/ -- <b><i>The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology approaches is expanding treatment options. Additionally, the launch of emerging drugs such as Tinengotinib (TransThera Sciences), Rilvegostomig (AstraZeneca), Nanvuranlat (JPH203) (J-Pharma/<span value="ACORN:3216571029" idsrc="xmltag.org" >OHARA Pharmaceutical</span>), Tovecimig (CTX-009) (<span value="NASDAQ-NMS:CMPX" idsrc="xmltag.org" >Compass Therapeutics</span>), Lenvatinib mesylate (LENVIMA) (<span value="NYSE:MRK" idsrc="xmltag.org" >Merck</span>/Eisai), and others will further boost the market growth.</i></b></p> <div id="prni_dvprnejpg7689left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg7689left" title="DelveInsight Logo" src="https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg" alt="DelveInsight Logo" align="middle" /></div><p>Recently published Biliary Tract http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html Mon, 02 Mar 2026 17:31:00 -0400 2RH A.20986375 A.21423504 A.32165710 A.33353809 A.34272207 A.39985803 A.40151759 A.50100157 A.50113798 A.50113881 A.50114197 A.50202178 A.50202556 A.60012004 BOLD CMPX INCY JAZZ LLY LOXO MRK O.00000313 O.00002198 O.00037438 O.00050368 O.00052901 O.00160346 O.00160456 O.00637617 O.00644488 O.00823584 O.01304637 O.03044482 O.07639287 O.08528768 O.12498162 O.13804664 O.15817313 O.18722415 O.38725784 O.39100698 O.40271399 O.49925668 O.51354437 O.54940956 O.55342982 PFE RDHL REPL RLAY ROG S1GE34 SGEN http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 2, 2026</chron></span> /PRNewswire/ -- <b><i>The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology approaches is expanding treatment options. Additionally, the launch of emerging drugs such as Tinengotinib (TransThera Sciences), Rilvegostomig (AstraZeneca), Nanvuranlat (JPH203) (J-Pharma/<span value="ACORN:3216571029" idsrc="xmltag.org" >OHARA Pharmaceutical</span>), Tovecimig (CTX-009) (<span value="NASDAQ-NMS:CMPX" idsrc="xmltag.org" >Compass Therapeutics</span>), Lenvatinib mesylate (LENVIMA) (<span value="NYSE:MRK" idsrc="xmltag.org" >Merck</span>/Eisai), and others will further boost the market growth.</i></b></p> <div id="prni_dvprnejpg7689left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg7689left" title="DelveInsight Logo" src="https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg" alt="DelveInsight Logo" align="middle" /></div><p>Recently published Biliary Tract http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html Mon, 02 Mar 2026 17:31:00 -0400 2RH A.20986375 A.21423504 A.32165710 A.33353809 A.34272207 A.39985803 A.40151759 A.50100157 A.50113798 A.50113881 A.50114197 A.50202178 A.50202556 A.60012004 BOLD CMPX INCY JAZZ LLY LOXO MRK O.00000313 O.00002198 O.00037438 O.00050368 O.00052901 O.00160346 O.00160456 O.00637617 O.00644488 O.00823584 O.01304637 O.03044482 O.07639287 O.08528768 O.12498162 O.13804664 O.15817313 O.18722415 O.38725784 O.39100698 O.40271399 O.49925668 O.51354437 O.54940956 O.55342982 PFE RDHL REPL RLAY ROG S1GE34 SGEN http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 2, 2026</chron></span> /PRNewswire/ -- <b><i>The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology approaches is expanding treatment options. Additionally, the launch of emerging drugs such as Tinengotinib (TransThera Sciences), Rilvegostomig (AstraZeneca), Nanvuranlat (JPH203) (J-Pharma/<span value="ACORN:3216571029" idsrc="xmltag.org" >OHARA Pharmaceutical</span>), Tovecimig (CTX-009) (<span value="NASDAQ-NMS:CMPX" idsrc="xmltag.org" >Compass Therapeutics</span>), Lenvatinib mesylate (LENVIMA) (<span value="NYSE:MRK" idsrc="xmltag.org" >Merck</span>/Eisai), and others will further boost the market growth.</i></b></p> <div id="prni_dvprnejpg7689left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg7689left" title="DelveInsight Logo" src="https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg" alt="DelveInsight Logo" align="middle" /></div><p>Recently published Biliary Tract http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html Mon, 02 Mar 2026 17:31:00 -0400 2RH A.20986375 A.21423504 A.32165710 A.33353809 A.34272207 A.39985803 A.40151759 A.50100157 A.50113798 A.50113881 A.50114197 A.50202178 A.50202556 A.60012004 BOLD CMPX INCY JAZZ LLY LOXO MRK O.00000313 O.00002198 O.00037438 O.00050368 O.00052901 O.00160346 O.00160456 O.00637617 O.00644488 O.00823584 O.01304637 O.03044482 O.07639287 O.08528768 O.12498162 O.13804664 O.15817313 O.18722415 O.38725784 O.39100698 O.40271399 O.49925668 O.51354437 O.54940956 O.55342982 PFE RDHL REPL RLAY ROG S1GE34 SGEN http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 2, 2026</chron></span> /PRNewswire/ -- <b><i>The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology approaches is expanding treatment options. Additionally, the launch of emerging drugs such as Tinengotinib (TransThera Sciences), Rilvegostomig (AstraZeneca), Nanvuranlat (JPH203) (J-Pharma/<span value="ACORN:3216571029" idsrc="xmltag.org" >OHARA Pharmaceutical</span>), Tovecimig (CTX-009) (<span value="NASDAQ-NMS:CMPX" idsrc="xmltag.org" >Compass Therapeutics</span>), Lenvatinib mesylate (LENVIMA) (<span value="NYSE:MRK" idsrc="xmltag.org" >Merck</span>/Eisai), and others will further boost the market growth.</i></b></p> <div id="prni_dvprnejpg7689left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg7689left" title="DelveInsight Logo" src="https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg" alt="DelveInsight Logo" align="middle" /></div><p>Recently published Biliary Tract http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html Mon, 02 Mar 2026 17:31:00 -0400 2RH A.20986375 A.21423504 A.32165710 A.33353809 A.34272207 A.39985803 A.40151759 A.50100157 A.50113798 A.50113881 A.50114197 A.50202178 A.50202556 A.60012004 BOLD CMPX INCY JAZZ LLY LOXO MRK O.00000313 O.00002198 O.00037438 O.00050368 O.00052901 O.00160346 O.00160456 O.00637617 O.00644488 O.00823584 O.01304637 O.03044482 O.07639287 O.08528768 O.12498162 O.13804664 O.15817313 O.18722415 O.38725784 O.39100698 O.40271399 O.49925668 O.51354437 O.54940956 O.55342982 PFE RDHL REPL RLAY ROG S1GE34 SGEN http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 2, 2026</chron></span> /PRNewswire/ -- <b><i>The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology approaches is expanding treatment options. Additionally, the launch of emerging drugs such as Tinengotinib (TransThera Sciences), Rilvegostomig (AstraZeneca), Nanvuranlat (JPH203) (J-Pharma/<span value="ACORN:3216571029" idsrc="xmltag.org" >OHARA Pharmaceutical</span>), Tovecimig (CTX-009) (<span value="NASDAQ-NMS:CMPX" idsrc="xmltag.org" >Compass Therapeutics</span>), Lenvatinib mesylate (LENVIMA) (<span value="NYSE:MRK" idsrc="xmltag.org" >Merck</span>/Eisai), and others will further boost the market growth.</i></b></p> <div id="prni_dvprnejpg7689left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg7689left" title="DelveInsight Logo" src="https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg" alt="DelveInsight Logo" align="middle" /></div><p>Recently published Biliary Tract http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html Mon, 02 Mar 2026 17:31:00 -0400 2RH A.20986375 A.21423504 A.32165710 A.33353809 A.34272207 A.39985803 A.40151759 A.50100157 A.50113798 A.50113881 A.50114197 A.50202178 A.50202556 A.60012004 BOLD CMPX INCY JAZZ LLY LOXO MRK O.00000313 O.00002198 O.00037438 O.00050368 O.00052901 O.00160346 O.00160456 O.00637617 O.00644488 O.00823584 O.01304637 O.03044482 O.07639287 O.08528768 O.12498162 O.13804664 O.15817313 O.18722415 O.38725784 O.39100698 O.40271399 O.49925668 O.51354437 O.54940956 O.55342982 PFE RDHL REPL RLAY ROG S1GE34 SGEN http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 2, 2026</chron></span> /PRNewswire/ -- <b><i>The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology approaches is expanding treatment options. Additionally, the launch of emerging drugs such as Tinengotinib (TransThera Sciences), Rilvegostomig (AstraZeneca), Nanvuranlat (JPH203) (J-Pharma/<span value="ACORN:3216571029" idsrc="xmltag.org" >OHARA Pharmaceutical</span>), Tovecimig (CTX-009) (<span value="NASDAQ-NMS:CMPX" idsrc="xmltag.org" >Compass Therapeutics</span>), Lenvatinib mesylate (LENVIMA) (<span value="NYSE:MRK" idsrc="xmltag.org" >Merck</span>/Eisai), and others will further boost the market growth.</i></b></p> <div id="prni_dvprnejpg7689left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg7689left" title="DelveInsight Logo" src="https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg" alt="DelveInsight Logo" align="middle" /></div><p>Recently published Biliary Tract http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html Mon, 02 Mar 2026 17:31:00 -0400 2RH A.20986375 A.21423504 A.32165710 A.33353809 A.34272207 A.39985803 A.40151759 A.50100157 A.50113798 A.50113881 A.50114197 A.50202178 A.50202556 A.60012004 BOLD CMPX INCY JAZZ LLY LOXO MRK O.00000313 O.00002198 O.00037438 O.00050368 O.00052901 O.00160346 O.00160456 O.00637617 O.00644488 O.00823584 O.01304637 O.03044482 O.07639287 O.08528768 O.12498162 O.13804664 O.15817313 O.18722415 O.38725784 O.39100698 O.40271399 O.49925668 O.51354437 O.54940956 O.55342982 PFE RDHL REPL RLAY ROG S1GE34 SGEN http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 2, 2026</chron></span> /PRNewswire/ -- <b><i>The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology approaches is expanding treatment options. Additionally, the launch of emerging drugs such as Tinengotinib (TransThera Sciences), Rilvegostomig (AstraZeneca), Nanvuranlat (JPH203) (J-Pharma/<span value="ACORN:3216571029" idsrc="xmltag.org" >OHARA Pharmaceutical</span>), Tovecimig (CTX-009) (<span value="NASDAQ-NMS:CMPX" idsrc="xmltag.org" >Compass Therapeutics</span>), Lenvatinib mesylate (LENVIMA) (<span value="NYSE:MRK" idsrc="xmltag.org" >Merck</span>/Eisai), and others will further boost the market growth.</i></b></p> <div id="prni_dvprnejpg7689left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg7689left" title="DelveInsight Logo" src="https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg" alt="DelveInsight Logo" align="middle" /></div><p>Recently published Biliary Tract http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html Mon, 02 Mar 2026 17:31:00 -0400 2RH A.20986375 A.21423504 A.32165710 A.33353809 A.34272207 A.39985803 A.40151759 A.50100157 A.50113798 A.50113881 A.50114197 A.50202178 A.50202556 A.60012004 BOLD CMPX INCY JAZZ LLY LOXO MRK O.00000313 O.00002198 O.00037438 O.00050368 O.00052901 O.00160346 O.00160456 O.00637617 O.00644488 O.00823584 O.01304637 O.03044482 O.07639287 O.08528768 O.12498162 O.13804664 O.15817313 O.18722415 O.38725784 O.39100698 O.40271399 O.49925668 O.51354437 O.54940956 O.55342982 PFE RDHL REPL RLAY ROG S1GE34 SGEN http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 2, 2026</chron></span> /PRNewswire/ -- <b><i>The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology approaches is expanding treatment options. Additionally, the launch of emerging drugs such as Tinengotinib (TransThera Sciences), Rilvegostomig (AstraZeneca), Nanvuranlat (JPH203) (J-Pharma/<span value="ACORN:3216571029" idsrc="xmltag.org" >OHARA Pharmaceutical</span>), Tovecimig (CTX-009) (<span value="NASDAQ-NMS:CMPX" idsrc="xmltag.org" >Compass Therapeutics</span>), Lenvatinib mesylate (LENVIMA) (<span value="NYSE:MRK" idsrc="xmltag.org" >Merck</span>/Eisai), and others will further boost the market growth.</i></b></p> <div id="prni_dvprnejpg7689left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg7689left" title="DelveInsight Logo" src="https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg" alt="DelveInsight Logo" align="middle" /></div><p>Recently published Biliary Tract http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html Mon, 02 Mar 2026 17:31:00 -0400 2RH A.20986375 A.21423504 A.32165710 A.33353809 A.34272207 A.39985803 A.40151759 A.50100157 A.50113798 A.50113881 A.50114197 A.50202178 A.50202556 A.60012004 BOLD CMPX INCY JAZZ LLY LOXO MRK O.00000313 O.00002198 O.00037438 O.00050368 O.00052901 O.00160346 O.00160456 O.00637617 O.00644488 O.00823584 O.01304637 O.03044482 O.07639287 O.08528768 O.12498162 O.13804664 O.15817313 O.18722415 O.38725784 O.39100698 O.40271399 O.49925668 O.51354437 O.54940956 O.55342982 PFE RDHL REPL RLAY ROG S1GE34 SGEN http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 2, 2026</chron></span> /PRNewswire/ -- <b><i>The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology approaches is expanding treatment options. Additionally, the launch of emerging drugs such as Tinengotinib (TransThera Sciences), Rilvegostomig (AstraZeneca), Nanvuranlat (JPH203) (J-Pharma/<span value="ACORN:3216571029" idsrc="xmltag.org" >OHARA Pharmaceutical</span>), Tovecimig (CTX-009) (<span value="NASDAQ-NMS:CMPX" idsrc="xmltag.org" >Compass Therapeutics</span>), Lenvatinib mesylate (LENVIMA) (<span value="NYSE:MRK" idsrc="xmltag.org" >Merck</span>/Eisai), and others will further boost the market growth.</i></b></p> <div id="prni_dvprnejpg7689left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg7689left" title="DelveInsight Logo" src="https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg" alt="DelveInsight Logo" align="middle" /></div><p>Recently published Biliary Tract http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html Mon, 02 Mar 2026 17:31:00 -0400 2RH A.20986375 A.21423504 A.32165710 A.33353809 A.34272207 A.39985803 A.40151759 A.50100157 A.50113798 A.50113881 A.50114197 A.50202178 A.50202556 A.60012004 BOLD CMPX INCY JAZZ LLY LOXO MRK O.00000313 O.00002198 O.00037438 O.00050368 O.00052901 O.00160346 O.00160456 O.00637617 O.00644488 O.00823584 O.01304637 O.03044482 O.07639287 O.08528768 O.12498162 O.13804664 O.15817313 O.18722415 O.38725784 O.39100698 O.40271399 O.49925668 O.51354437 O.54940956 O.55342982 PFE RDHL REPL RLAY ROG S1GE34 SGEN http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 2, 2026</chron></span> /PRNewswire/ -- <b><i>The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology approaches is expanding treatment options. Additionally, the launch of emerging drugs such as Tinengotinib (TransThera Sciences), Rilvegostomig (AstraZeneca), Nanvuranlat (JPH203) (J-Pharma/<span value="ACORN:3216571029" idsrc="xmltag.org" >OHARA Pharmaceutical</span>), Tovecimig (CTX-009) (<span value="NASDAQ-NMS:CMPX" idsrc="xmltag.org" >Compass Therapeutics</span>), Lenvatinib mesylate (LENVIMA) (<span value="NYSE:MRK" idsrc="xmltag.org" >Merck</span>/Eisai), and others will further boost the market growth.</i></b></p> <div id="prni_dvprnejpg7689left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg7689left" title="DelveInsight Logo" src="https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg" alt="DelveInsight Logo" align="middle" /></div><p>Recently published Biliary Tract http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html Mon, 02 Mar 2026 17:31:00 -0400 2RH A.20986375 A.21423504 A.32165710 A.33353809 A.34272207 A.39985803 A.40151759 A.50100157 A.50113798 A.50113881 A.50114197 A.50202178 A.50202556 A.60012004 BOLD CMPX INCY JAZZ LLY LOXO MRK O.00000313 O.00002198 O.00037438 O.00050368 O.00052901 O.00160346 O.00160456 O.00637617 O.00644488 O.00823584 O.01304637 O.03044482 O.07639287 O.08528768 O.12498162 O.13804664 O.15817313 O.18722415 O.38725784 O.39100698 O.40271399 O.49925668 O.51354437 O.54940956 O.55342982 PFE RDHL REPL RLAY ROG S1GE34 SGEN http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 2, 2026</chron></span> /PRNewswire/ -- <b><i>The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology approaches is expanding treatment options. Additionally, the launch of emerging drugs such as Tinengotinib (TransThera Sciences), Rilvegostomig (AstraZeneca), Nanvuranlat (JPH203) (J-Pharma/<span value="ACORN:3216571029" idsrc="xmltag.org" >OHARA Pharmaceutical</span>), Tovecimig (CTX-009) (<span value="NASDAQ-NMS:CMPX" idsrc="xmltag.org" >Compass Therapeutics</span>), Lenvatinib mesylate (LENVIMA) (<span value="NYSE:MRK" idsrc="xmltag.org" >Merck</span>/Eisai), and others will further boost the market growth.</i></b></p> <div id="prni_dvprnejpg7689left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg7689left" title="DelveInsight Logo" src="https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg" alt="DelveInsight Logo" align="middle" /></div><p>Recently published Biliary Tract http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html Mon, 02 Mar 2026 17:31:00 -0400 2RH A.20986375 A.21423504 A.32165710 A.33353809 A.34272207 A.39985803 A.40151759 A.50100157 A.50113798 A.50113881 A.50114197 A.50202178 A.50202556 A.60012004 BOLD CMPX INCY JAZZ LLY LOXO MRK O.00000313 O.00002198 O.00037438 O.00050368 O.00052901 O.00160346 O.00160456 O.00637617 O.00644488 O.00823584 O.01304637 O.03044482 O.07639287 O.08528768 O.12498162 O.13804664 O.15817313 O.18722415 O.38725784 O.39100698 O.40271399 O.49925668 O.51354437 O.54940956 O.55342982 PFE RDHL REPL RLAY ROG S1GE34 SGEN http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 2, 2026</chron></span> /PRNewswire/ -- <b><i>The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology approaches is expanding treatment options. Additionally, the launch of emerging drugs such as Tinengotinib (TransThera Sciences), Rilvegostomig (AstraZeneca), Nanvuranlat (JPH203) (J-Pharma/<span value="ACORN:3216571029" idsrc="xmltag.org" >OHARA Pharmaceutical</span>), Tovecimig (CTX-009) (<span value="NASDAQ-NMS:CMPX" idsrc="xmltag.org" >Compass Therapeutics</span>), Lenvatinib mesylate (LENVIMA) (<span value="NYSE:MRK" idsrc="xmltag.org" >Merck</span>/Eisai), and others will further boost the market growth.</i></b></p> <div id="prni_dvprnejpg7689left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg7689left" title="DelveInsight Logo" src="https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg" alt="DelveInsight Logo" align="middle" /></div><p>Recently published Biliary Tract http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html Mon, 02 Mar 2026 17:31:00 -0400 2RH A.20986375 A.21423504 A.32165710 A.33353809 A.34272207 A.39985803 A.40151759 A.50100157 A.50113798 A.50113881 A.50114197 A.50202178 A.50202556 A.60012004 BOLD CMPX INCY JAZZ LLY LOXO MRK O.00000313 O.00002198 O.00037438 O.00050368 O.00052901 O.00160346 O.00160456 O.00637617 O.00644488 O.00823584 O.01304637 O.03044482 O.07639287 O.08528768 O.12498162 O.13804664 O.15817313 O.18722415 O.38725784 O.39100698 O.40271399 O.49925668 O.51354437 O.54940956 O.55342982 PFE RDHL REPL RLAY ROG S1GE34 SGEN http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 2, 2026</chron></span> /PRNewswire/ -- <b><i>The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology approaches is expanding treatment options. Additionally, the launch of emerging drugs such as Tinengotinib (TransThera Sciences), Rilvegostomig (AstraZeneca), Nanvuranlat (JPH203) (J-Pharma/<span value="ACORN:3216571029" idsrc="xmltag.org" >OHARA Pharmaceutical</span>), Tovecimig (CTX-009) (<span value="NASDAQ-NMS:CMPX" idsrc="xmltag.org" >Compass Therapeutics</span>), Lenvatinib mesylate (LENVIMA) (<span value="NYSE:MRK" idsrc="xmltag.org" >Merck</span>/Eisai), and others will further boost the market growth.</i></b></p> <div id="prni_dvprnejpg7689left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg7689left" title="DelveInsight Logo" src="https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg" alt="DelveInsight Logo" align="middle" /></div><p>Recently published Biliary Tract http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html Mon, 02 Mar 2026 17:31:00 -0400 2RH A.20986375 A.21423504 A.32165710 A.33353809 A.34272207 A.39985803 A.40151759 A.50100157 A.50113798 A.50113881 A.50114197 A.50202178 A.50202556 A.60012004 BOLD CMPX INCY JAZZ LLY LOXO MRK O.00000313 O.00002198 O.00037438 O.00050368 O.00052901 O.00160346 O.00160456 O.00637617 O.00644488 O.00823584 O.01304637 O.03044482 O.07639287 O.08528768 O.12498162 O.13804664 O.15817313 O.18722415 O.38725784 O.39100698 O.40271399 O.49925668 O.51354437 O.54940956 O.55342982 PFE RDHL REPL RLAY ROG S1GE34 SGEN http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 2, 2026</chron></span> /PRNewswire/ -- <b><i>The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology approaches is expanding treatment options. Additionally, the launch of emerging drugs such as Tinengotinib (TransThera Sciences), Rilvegostomig (AstraZeneca), Nanvuranlat (JPH203) (J-Pharma/<span value="ACORN:3216571029" idsrc="xmltag.org" >OHARA Pharmaceutical</span>), Tovecimig (CTX-009) (<span value="NASDAQ-NMS:CMPX" idsrc="xmltag.org" >Compass Therapeutics</span>), Lenvatinib mesylate (LENVIMA) (<span value="NYSE:MRK" idsrc="xmltag.org" >Merck</span>/Eisai), and others will further boost the market growth.</i></b></p> <div id="prni_dvprnejpg7689left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg7689left" title="DelveInsight Logo" src="https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg" alt="DelveInsight Logo" align="middle" /></div><p>Recently published Biliary Tract http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html Mon, 02 Mar 2026 17:31:00 -0400 2RH A.20986375 A.21423504 A.32165710 A.33353809 A.34272207 A.39985803 A.40151759 A.50100157 A.50113798 A.50113881 A.50114197 A.50202178 A.50202556 A.60012004 BOLD CMPX INCY JAZZ LLY LOXO MRK O.00000313 O.00002198 O.00037438 O.00050368 O.00052901 O.00160346 O.00160456 O.00637617 O.00644488 O.00823584 O.01304637 O.03044482 O.07639287 O.08528768 O.12498162 O.13804664 O.15817313 O.18722415 O.38725784 O.39100698 O.40271399 O.49925668 O.51354437 O.54940956 O.55342982 PFE RDHL REPL RLAY ROG S1GE34 SGEN